COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
08/08/2025
Tuesday, 19 August 2025 at 11.00 - 12.00h CEST In connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a [...]
Sai Life Sciences Limited Reports Revenue growth of 77% YoY
08/08/2025
Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 Cr HYDERABAD, India, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
08/08/2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half [...]
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
08/08/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Nicox Extends Existing Flexible Equity Financing
08/08/2025
Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid- [...]
Nicox étend sa ligne de financement flexible existante
08/08/2025
Communiqué de presse Nicox étend sa ligne de financement flexible existante 5 millions d’actions ajoutées à la ligne de financement en fonds propres existante avec Vester Finance Les premiers résultats de l’étude [...]
BioVie Inc. Announces Pricing of $12 Million Public Offering
08/08/2025
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
08/08/2025
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/08/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 Date Nombre total d’actions composant le [...]
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
07/08/2025
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs [...]
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07/08/2025
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final [...]
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
07/08/2025
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development [...]
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
07/08/2025
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and [...]
Globus Medical Reports Second Quarter 2025 Results
07/08/2025
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net [...]
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
07/08/2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will [...]
AMN Healthcare Announces Second Quarter 2025 Results
07/08/2025
Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02) /share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the [...]
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track [...]
TerrAscend Reports Second Quarter 2025 Financial Results
07/08/2025
Net Revenue totaled $65 million and Gross Profit Margin was 51.1% from continuing operations, excluding Michigan 12 th consecutive quarter of positive Cash Flow from continuing operations and 8 th consecutive quarter of [...]
Biodesix Announces Second Quarter 2025 Results and Highlights
07/08/2025
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference [...]

Pages